Cancer Genetics and Epigenetics 2024, Vol.12, No.5, 234-253 http://medscipublisher.com/index.php/cge 247 Azadi A., Golchini A., Delazar S., Kahaki F.A., Dehnavi S.M., Payandeh Z., and Eyvazi S., 2021, Recent advances on immune targeted therapy of colorectal cancer using bi-specific antibodies and therapeutic vaccines, Biological Procedures Online, 23(1): 13. https://doi.org/10.1186/s12575-021-00147-7 PMID: 34193050 PMCID: PMC8245152 Bader J.E., Voss K., and Rathmell J.C., 2020, Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy, Molecular Cell, 78(6): 1019-1033. https://doi.org/10.1016/j.molcel.2020.05.034 Bao X.W., Zhang H.Y., Wu W., Cheng S.B., Dai X.M., Zhu X.D., Fu Q.H., Tong Z., Liu L.L., Zheng Y., Zhao P., Fang W.J., and Liu F.L., 2020, Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy, Journal for Immunotherapy of Cancer, 8(2): e001437. https://doi.org/10.1136/jitc-2020-001437 Bassetti M.F., Turk A.A., Lubner S.J., Uboha,N.V., LoConte N.K., Mulkerin D., Kim D.H., Matkowskyj K., Weber S.M., Abbott D., Eickhoff J.C., and Deming D.A., 2019, A phase Ib study of pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver metastatic MSS colorectal cancer (CRC): A postoperative safety analysis, Journal of Clinical Oncology, 37: e15047-e15047. https://doi.org/10.1200/JCO.2019.37.15_suppl.e15047 PMID: 33028695 PMCID: PMC7542666 Bikhchandani M., Amersi F., Hendifar A., Gangi A., Osipov A., Zaghiyan K., Atkins K., Cho M., Aguirre F., Hazelett D., Alvarez R., Zhou L.S., Megan Hitchins M., and Gong J., 2023, POLE-mutant colon cancer treated with PD-1 blockade showing clearance of circulating tumor DNA and prolonged disease-free interval, Genes, 14(5): 1054. https://doi.org/10.3390/genes14051054 PMID: 37239414 PMCID: PMC10218075 Bullock A., Grossman, J., Fakih, M., Lenz, H., Gordon, M., Margolin, K., Wilky, B., Mahadevan, D., Trent, J., Bockorny, B., Moser J., Balmanoukian A., Schlechter B., Feliu W.O., Rosenthal K., Bullock B., Stebbing J., Godwin J., O'Day S., Tsimberidou A., El-Khoueiry A., 2022, LBA O-9 Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer, Annals of Oncology, 33: S376. https://doi.org/10.1016/j.annonc.2022.04.453 Cao L.C., Li T., Ba Y., Chen E.F., Yang J., and Zhang H.Z., 2022, Exploring immune-related prognostic signatures in the tumor microenvironment of colon cancer, Frontiers in Genetics, 13: 801484. https://doi.org/10.3389/fgene.2022.801484 PMID: 35281839 PMCID: PMC8907673 Cen S.Y., Liu K., Zheng Y., Shan J.Z., Jing C., Gao J.L., Pan H.M., Bai Z.G., and Liu Z., 2021, BRAF mutation as a potential therapeutic target for checkpoint inhibitors: a comprehensive analysis of immune microenvironment in BRAF mutated colon cancer, Frontiers in Cell and Developmental Biology 9: 705060. https://doi.org/10.3389/fcell.2021.705060 PMID: 34381786 PMCID: PMC8350390 Chamseddine A.N., Assi, T., Mir O., and Chouaib S., 2022, Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: a TAM-pting approach, Pharmacology and Therapeutics, 231: 107986. https://doi.org/10.1016/j.pharmthera.2021.107986 Chen E.X., Jonker D.J., Loree J.M., Kennecke H.F., Berry S.R., Couture F., Ahmad C.E., Goffin J.R., Kavan P., Harb M., Colwell B., Samimi S., Samson B., Abbas T., Aucoin N., Aubin F., Koski S.L., Wei A.C., Magoski N.M., Tu D.S., and O'Callaghan C.J., 2020, Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the canadian cancer trials group CO.26 Study, JAMA Oncology, 6(6): 831-838. https://doi.org/10.1001/jamaoncol.2020.0910 PMID: 32379280 PMCID: PMC7206536 Cheng S.Y., Han Z.H., Dai D., Li F., Zhang X.T., Lu M., Lu Z., Wang X., Zhou J., Li J., Guo X.H., Song P.W., Qiu C.Z., Shen W., Zhang Q., Zhu N., Wang X., Tan Y., Kou Y., Yin X.C., Shen L., and Peng Z., 2024, Multi-omics of the gut microbial ecosystem in patients with microsatellite-instability-high gastrointestinal cancer resistant to immunotherapy. Cell Reports Medicine, 5(1): 101355. https://doi.org/10.1016/j.xcrm.2023.101355 Cook K.W., Durrant L.G., and Brentville V.A., 2018, Current strategies to enhance anti-tumour immunity, Biomedicines, 6(2): 37. https://doi.org/10.3390/biomedicines6020037 Cousin S., Cantarel C., Guegan J.P., Mazard T., Gomez-Roca C., Metges J.P., Bellera C., Adenis A., Korakis I., Poureau P.G., Bourcier K., Toulmonde M., Kind M., Rey C., Auzanneau C., Bessede A., Soubeyran I., and Italiano A., 2022, Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial, European Journal of Cancer, 162: 161-169. https://doi.org/10.1016/j.ejca.2021.11.012 Cuiffo B.G., Boone A., Yan D., Maxwell M., Rivest B., Cardia J., and Fricker S.P., 2023, Abstract 5113: INTASYL self-delivering RNAi therapeutic dual targeting PD-1 and CTLA-4 provides synergistic antitumor efficacy in the treatment of murine colon cancer in vivo, Cancer Research, 83(7_Supplement): 5113. https://doi.org/10.1158/1538-7445.AM2023-5113
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==